Novo Nordisk Executive Management Changes Announced
Novo Nordisk, a prominent global healthcare firm, has announced important updates within its Executive Management team, marking a new chapter in its leadership journey.
Key Leadership Changes
With 28 years at Novo Nordisk and seven years leading Commercial Strategy & Corporate Affairs, Camilla Sylvest has chosen to depart the company. In light of her departure, notable organizational changes will take effect, signifying a strategic shift in management responsibilities.
Ludovic Helfgott, previously the Executive Vice President for Rare Disease, will now oversee Product & Portfolio Strategy. This expands his role significantly, encompassing commercial strategy, medical affairs, and business development across all therapy areas. Joining Novo Nordisk in 2019, Ludovic has successfully established a strategic Rare Disease portfolio, bringing with him experience from AstraZeneca where he managed various therapy portfolios.
Promotions and New Responsibilities
In an exciting development, Thilde Hummel Bøgebjerg has been elevated from Senior Vice President of Product Supply Emerging Technologies to Executive Vice President of Quality, IT & Environmental Affairs. Her 18-year tenure at Novo Nordisk has seen her take on numerous leadership roles, demonstrating exceptional skill in areas including Product Supply and CMC development.
Tania Sabroe, Executive Vice President of People & Organisation, will now also lead Global Communication alongside her existing responsibilities. This dual role will enhance the integration of communications strategies across the organization.
Updated Executive Management Team
As this transition unfolds, Novo Nordisk's Executive Management will comprise a talented team of leaders dedicated to driving innovation in chronic disease treatment:
- Lars Fruergaard Jørgensen, President and CEO*
- Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs
- Maziar Mike Doustdar, EVP, International Operations
- Ludovic Helfgott, EVP, Product & Portfolio Strategy
- Karsten Munk Knudsen, EVP, Chief Financial Officer*
- Martin Holst Lange, EVP, Development
- Dave Moore, EVP, US Operations
- Tania Sabroe, EVP, People, Organisation and Communication
- Marcus Schindler, EVP, Chief Scientific Officer, Research & Early Development
- Henrik Wulff, EVP, Product Supply
* Registered as an executive with the Danish Business Authority.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that has been at the forefront of confronting serious chronic diseases since its inception in 1923. With its headquarters in Denmark, the company is driven by a mission to advance scientific research and enhance patient access to effective therapies. Currently employing around 76,300 people across 80 countries, Novo Nordisk's products reach approximately 170 nations worldwide. The company's B shares are traded on Nasdaq Copenhagen under the ticker symbol Novo-B, with American Depository Receipts listed on the New York Stock Exchange as NVO.
The company is dedicated to pioneering innovative solutions and expanding access to its therapies, aiming not only to treat but to prevent chronic conditions, enhancing life quality for millions.
Contact Information
If you have any inquiries regarding the changes or would like further information, please reach out to:
Media Contacts
Lars Otto Andersen-Lange
Phone: +45 3448 1298
Email: kolg@novonordisk.com
Liz Skrbkova (US)
Phone: +1 609 917 0632
Email: lzsk@novonordisk.com
Investor Relations
Jacob Martin Wiborg Rode
Phone: +45 3075 5956
Email: jrde@novonordisk.com
Ida Schaap Melvold
Phone: +45 3077 5649
Email: idmg@novonordisk.com
Sina Meyer
Phone: +45 3079 6656
Email: azey@novonordisk.com
Max Ung
Phone: +45 3077 6414
Email: mxun@novonordisk.com
Frederik Taylor Pitter
Phone: +1 609 613 0568
Email: fptr@novonordisk.com
Frequently Asked Questions
What are the key changes in Novo Nordisk's Executive Management?
Recent changes include Camilla Sylvest's departure and new roles for Ludovic Helfgott, Thilde Hummel Bøgebjerg, and Tania Sabroe.
Who will oversee Product & Portfolio Strategy?
Ludovic Helfgott will now be responsible for Product & Portfolio Strategy alongside his previous duties.
What is Thilde Bøgebjerg's new position?
Thilde Hummel Bøgebjerg has been promoted to Executive Vice President, Quality, IT & Environmental Affairs.
How long has Novo Nordisk been in operation?
Novo Nordisk was founded in 1923 and has grown into a major global healthcare company.
How does Novo Nordisk ensure innovation in healthcare?
The company focuses on pioneering scientific advancements and expanding access to essential medicines to improve patient outcomes worldwide.
